Fadrozole

A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.

Also Known As:

CGS 020286A; CGS-020286A; CGS-16949A; CGS020286A; FAD 286; FAD-286; FAD286; Fadrozole Hydrochloride; Fadrozole Monohydrochloride; CGS 16949A; CGS16949A; Hydrochloride, Fadrozole; Monohydrochloride, Fadrozole; Benzonitrile, 4-(5,6,7,8-tetrahydroimidazo(1,5-a)pyridin-5-yl)-

Networked: 105 relevant articles (13 outcomes, 27 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jeng, Arco Y: 6 articles (09/2010 - 06/2005)
2.	Huang, Bing S: 3 articles (09/2013 - 02/2009)
3.	Leenen, Frans H H: 3 articles (09/2013 - 02/2009)
4.	White, Roselyn A: 3 articles (09/2013 - 02/2009)
5.	Deliyanti, Devy: 2 articles (01/2020 - 03/2012)
6.	Wilkinson-Berka, Jennifer L: 2 articles (01/2020 - 03/2012)
7.	Bornstein, Stefan R: 2 articles (06/2017 - 10/2016)
8.	Brown, Nicholas F: 2 articles (06/2017 - 10/2016)
9.	Brunssen, Coy: 2 articles (06/2017 - 10/2016)
10.	Eisenhofer, Graeme: 2 articles (06/2017 - 10/2016)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 08/15/1996 - "This study confirms modest activity of fadrozole hydrochloride in a heterogeneous group of patients with breast carcinoma treated at three different dose levels." 08/15/1996 - "This was a prospective, randomized, Phase II study of fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. " 01/01/1994 - "To resolve these issues, a double-blind randomised endocrine study of three doses of fadrozole hydrochloride [0.5 mg twice daily (bd); 1.0 mg bd; 2.0 mg bd] was conducted in 80 (68 evaluable) postmenopausal patients with advanced breast cancer over a period of 3 months. " 03/15/1990 - "In this Phase I trial, 16 heavily pretreated postmenopausal patients with metastatic breast cancer were treated with escalating doses of CGS 16949A from 0.6 to 16 mg total daily oral dose. " 06/01/1999 - "[Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer]."
2.	Neoplasms (Cancer) 07/01/1996 - "Tumor size in the OCT+CGS 16949A group was significantly decreased compared with that in the OCT or CGS 16949A alone. " 06/01/1994 - "The antiproliferative effect of CGS 16949A on the post-menopausal model of DMBA-induced rat mammary tumor was studied. " 06/01/1994 - "A daily treatment of 0.5 mg/kg CGS 16949A was more effective than the once every 7 days treatment of 14 mg/kg on the tumor growth. " 02/15/1988 - "Tumors, which were allowed to regrow after a first treatment with CGS 16949A, were similarly efficaciously suppressed with a second treatment with CGS 16949A. " 02/15/1988 - "treatment of tumor-bearing rats for 42 days with CGS 16949A at doses of 1.0 to 8.0 mg/kg caused almost complete regression of palpable tumors and almost totally suppressed the appearance of new tumors. "
3.	Neoplasm Metastasis (Metastasis) 06/01/1999 - "Eleven recurrent postmenopausal breast cancer patients with osseous or lung metastases were received fadrozole hydrochloride at a dose of 1 mg twice a day for more than 8 weeks. " 10/01/1999 - "Chemoendocrine therapies using 5'-DFUR or CMitF in addition to TAM and fadrozole hydrochloride hydrate had developed progressive disease for liver metastasis. " 12/01/2001 - "[An elderly woman with breast cancer and multiple liver metastasis that responded well to combination therapy of fadrozole and tamoxifen]." 11/01/2001 - "Case 2: A 61-year-old woman was treated with CMF therapy, 5'-DFUR, tamoxifen, MPA fadrozole and pamidronate for bone metastasis and local recurrence. " 08/01/2000 - "She was diagnosed as having bone metastases and treated using pamidronate therapy with doxifluridine, tamoxifen and fadrozole, which was assessed as effective. "
4.	Endometriosis 02/01/1996 - "The present study strongly indicates that the new selective aromatase inhibitor fadrozole should be useful for the treatment of endometriosis." 02/01/1996 - "Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats." 02/01/1996 - "The therapeutic effect of the new nonsteroidal aromatase inhibitor fadrozole hydrochloride (4-(5,6,7,8-tetrahydro-imidazo[1,5a]pyridin-5-yl)benzonitrile monohydrochloride, fadrozole, CAS 102676-31-3, CGS16949A) was assessed using a surgically induced endometriosis model in rats. "
5.	Nausea 03/01/1990 - "Two further patients treated with 2 mg twice a day experienced persistent nausea which improved after dose reduction, and one patient, treated with 0.3 mg twice daily, developed a vasculitic rash requiring discontinuation of CGS 16949A. " 06/15/1996 - "There were no clinically meaningful differences between the treatment groups in the incidence and severity of adverse experiences, except that weight gain, fluid retention, and dyspnea were observed in more patients in the megestrol acetate group compared with those receiving fadrozole HCL, whereas nausea and vomiting were observed in more patients in the fadrozole HCL group compared with those receiving megestrol acetate. " 06/15/1996 - "Adverse experiences were mild with both therapies, but megestrol acetate was associated wiht a higher frequency of weight gain, fluid retention and dyspnea, whereas fadrozole HCL was associated with a higher frequency of nausea and vomiting."

Related Drugs and Biologics

1.	Aromatase Inhibitors
2.	Letrozole (Femara)
3.	Tamoxifen
4.	Anastrozole (Arimidex)
5.	formestane
6.	exemestane (Aromasin)
7.	Cyclophosphamide (Cytoxan)
8.	Megestrol Acetate (Borea)
9.	Aromatase (CYP19)
10.	Aminoglutethimide (Cytadren)

Related Therapies and Procedures

1.	Therapeutics
2.	Ovariectomy (Oophorectomy)
3.	Drug Tapering
4.	Intraventricular Infusions
5.	Injections